Last reviewed · How we verify
VORICONAZOLE
At a glance
| Generic name | VORICONAZOLE |
|---|---|
| Drug class | Azole Antifungal [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2002 |
Approved indications
- Invasive Aspergillosis
- Candidemia in Non-neutropenic Patients
- Deep Tissue Candida Infections
- Esophageal Candidiasis
- Scedosporiosis and Fusariosis
Common side effects
- Visual disturbances
- Fever
- Nausea
- Rash
- Vomiting
- Chills
- Headache
- Liver function test increased
- Tachycardia
- Hallucinations
Serious adverse events
- Hepatic Toxicity
- Arrhythmias and QT Prolongation
- Infusion Related Reactions
- Severe Cutaneous Adverse Reactions
- Photosensitivity
- Renal Toxicity
Drug interactions
- Rifampin
- Rifabutin
- Efavirenz (400 mg every 24 hours)
- Efavirenz (300 mg every 24 hours)
- High-dose Ritonavir (400 mg every 12 hours)
- Low-dose Ritonavir (100 mg every 12 hours)
- Carbamazepine
- Long Acting Barbiturates (e.g., phenobarbital, mephobarbital)
- Phenytoin
- Letermovir
- St. John's Wort
Key clinical trials
- A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity (PHASE1)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (PHASE1, PHASE2)
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Study on the Drug Interaction Between Buagafuran and Voriconazole (PHASE1)
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |